Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model

Haematologica

Volumn 97, Issue 7, 2012, Pages 1020-1028

  Swift, Brenna E ^a,b   Williams, Brent A ^a,c   Kosaka, Yoko ^a   Wang, Xing Hua ^a   Medin, Jeffrey A ^a   Viswanathan, Sowmya ^a   Martinez Lopez, Joaquin ^a,d   Keating, Armand ^a,b,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Bioluminescent xenograft; Clonogenic; Cytotoxicity; Immunotherapy; Multiple myeloma; Natural killer cell lines

Indexed keywords

DNA ADENINE METHYLTRANSFERASE; METHYLCELLULOSE; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL RECEPTOR NKG2D;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; CANCER INHIBITION; CELL RENEWAL; CHROMIUM RELEASE; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; MOUSE; MULTIPLE MYELOMA; NATURAL KILLER CELL; NONHUMAN; TOXICITY TESTING; TUMOR ENGRAFTMENT;

ANIMALS; CELL LINE, TUMOR; CLONE CELLS; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; GENES, REPORTER; HUMANS; IMMUNOASSAY; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY, ADOPTIVE; INJECTIONS, INTRAVENOUS; KILLER CELLS, NATURAL; LUCIFERASES; LUMINESCENT MEASUREMENTS; MICE; MULTIPLE MYELOMA; RECEPTORS, NATURAL KILLER CELL; TRANSPLANTATION, HETEROLOGOUS; TUMOR STEM CELL ASSAY;

EID: 84863908333     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.054254     Document Type: Article

References (43)

1. Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111(6):2962-72.
2. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046-60.
3. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood. 2008;111(5):2521-6.
4. Martinez-Lopez J, Blade J, Mateos MV, Grande C, Alegre A, García-Laraña J, et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood. 2011;118(3):529-34.
5. Hamburger A, Salmon SE. Primary bioassay of human myeloma stem cells. J Clin Invest. 1977;60(4):846-54.
6. Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, Borrello I, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 2008;68(1):190-7.
7. Feng Y, Wen J, Mike P, Choi DS, Eshoa C, Shi ZZ, et al. Bone marrow stromal cells from myeloma patients support the growth of myeloma stem cells. Stem Cells Dev. 2010;19(9):1289-96.
8. Jakubikova J, Adamia S, Kost-Alimova M, Klippel S, Cervi D, Daley JF, et al. Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood. 2011;117(17):4409-19.
9. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, et al. Characterization of clonogenic multiple myeloma cells. Blood. 2004;103(6):2332-6.
10. Takahashi T, Lim B, Jamal N, Tritchler D, Lockwood G, McKinney S, et al. Colony growth and self renewal of plasma cell precursors in multiple myeloma. J Clin Oncol. 1985;3(12):1613-23.
11. Alici E, Konstantinidis KV, Sutlu T, Aints A, Gahrton G, Ljunggren HG, et al. Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model. Exp Hematol. 2007;35(12):1839-46.
12. Alici E, Sutlu T, Bjorkstrand B, Gilljam M, Stellan B, Nahi H, et al. Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood. 2008;111(6):3155-62.
13. Shi J, Tricot G, Szmania S, Rosen N, Garg TK, Malaviarachchi PA, et al. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol. 2008;143(5):641-53.
14. Frohn C, Hoppner M, Schlenke P, Kirchner H, Koritke P, Luhm J. Anti-myeloma activity of natural killer lymphocytes. Br J Haematol. 2002;119(3):660-4.
15. Feng X, Yan J, Wang Y, Zierath JR, Nordenskjold M, Henter JI, et al. The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells. Mol Immunol. 2010;47(14):2388-96.
16. Lokhorst H, Einsele H, Vesole D, Bruno B, San Miguel J, Perez-Simon JA, et al. International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. J Clin Oncol. 2010;28(29): 4521-30.
17. Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F, et al. A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma. NEJM. 2007;356(11):1110-20.
18. Tonn T, Becker S, Esser R, Schwabe D, Seifried E. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res. 2001;10(4):535-44.
19. Maki G, Hayes GM, Naji A, Tyler T, Carosella ED, Rouas-Freiss N, et al. NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G. Leukemia. 2008;22(5):998-1006.
20. Yan Y, Steinherz P, Klingemann HG, Dennig D, Childs BH, McGuirk J, et al. Antileukemia activity of a natural killer cell line against human leukemias. Clin Cancer Res. 1998;4 (11):2859-68.
21. Klingemann H, Wong E, Maki G. A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood. Biol Blood Marrow Transplant. 1996;2(2):68-75.
22. Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J, et al. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy. 2008;10(6):625-32.
23. Suck G, Branch DR, Smyth MJ, Miller RG, Vergidis J, Fahim S, et al. KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity. Exp Hematol. 2005;33(10): 1160-71.
24. Johnson TR, Massey RJ, Deinhardt F. Lymphocyte and antibody cytotoxicity to tumor cells measured by a micro-51 chromium release assay. Immunol Commun. 1972;1(3):247-61.
25. Ozdemir O, Ravindranath Y, Savasan S. Cellmediated cytotoxicity evaluation using monoclonal antibody staining for target or effector cells with annexinV/propidium iodide colabeling by fluorosphere-adjusted counts on three-color flow cytometry. Cytometry Part A: The Journal of the International Society for Analytical Cytology. 2003;56 (1):53-60.
26. Williams BA, Wang XH, Keating A. Clonogenic assays measure leukemia stem cell killing not detectable by chromium release and flow cytometric cytotoxicity assays. Cytotherapy. 2010;12(7):951-60.
27. Harnack U, Johnen H, Pecher G. Natural killer cell line YT exerts cytotoxicity against CD86+ Myeloma Cells. Anticancer Res. 2011;31(2):475-80.
28. Yagita M, Huang CL, Umehara H, Matsuo Y, Tabata R, Miyake M, et al. A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia. 2000;14(5):922-30.
29. Suck G, Branch DR, Aravena P, Mathieson M, Helke S, Keating A. Constitutively polarized granules prime KHYG-1 NK cells. Int Immunol. 2006;18(9):1347-54.
30. Suck G, Branch DR, Keating A. Irradiated KHYG-1 retains cytotoxicity: potential for adoptive immunotherapy with a natural killer cell line. Int J Radiat Biol. 2006;82 (5):355-61.
31. Carlson LM, Pahlman S, De Geer A, Kogner P, Levitskaya J. Differentiation induced by physiological and pharmacological stimuli leads to increased antigenicity of human neuroblastoma cells. Cell Res. 2008;18(3): 398-411.
32. El-Sherbiny YM, Meade JL, Holmes TD, McGonagle D, Mackie SL, Morgan AW, et al. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res. 2007;67(18):8444-9.
33. Carbone E, Neri P, Mesuraca M, Fulciniti MT, Otsuki T, Pende D, et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood. 2005;105 (1):251-8.
34. Pogge von Strandmann E, Simhadri VR, von Tresckow B, Sasse S, Reiners KS, Hansen HP, et al. Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity. 2007;27(6):965-74.
35. Soriani A, Zingoni A, Cerboni C, Iannitto ML, Ricciardi MR, Di Gialleonardo V, et al. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood. 2009;113(15):3503-11.
36. Fionda C, Soriani A, Malgarini G, Iannitto ML, Santoni A, Cippitelli M. Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation. J Immunol. 2009;183 (7):4385-94.
37. Noonan K, Matsui W, Serafini P, Carbley R, Tan G, Khalili J, et al. Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors. Cancer Res. 2005;65(5):2026-34.
38. Langenkamp U, Siegler U, Jorger S, Diermayr S, Gratwohl A, Kalberer CP, et al. Human acute myeloid leukemia CD34+CD38-stem cells are susceptible to allorecognition and lysis by single KIR-expressing natural killer cells. Haematologica. 2009;94(11):1590-4.
39. Rozemuller H, van der Spek E, Bogers-Boer LH, Zwart MC, Verweij V, Emmelot M, et al. A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect. Haematologica. 2008;93(7):1049-57.
40. Miyakawa Y, Ohnishi Y, Tomisawa M, Monnai M, Kohmura K, Ueyama Y, et al. Establishment of a new model of human multiple myeloma using NOD/SCID/gammac(null) (NOG) mice. Biochem Biophys Res Commun. 2004;313(2):258-62.
41. Mitsiades CS, Mitsiades NS, Bronson RT, Chauhan D, Munshi N, Treon SP, et al. Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Cancer Res. 2003;63(20):6689-96.
42. Pittsburgh Uo. ZRx-101 (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia. In: ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) Available from: http://wwwclinicaltrialsgov/ ct2/show/NCT00900809?te rm=NCT00900809&rank=1 NCT Identifier: NCT00900809. 2000-[cited 2011 Mar 16].
43. University Health Network T. Safety Study Looking at the Use of a Natural Killer Cell Line Against Hematological Malignancies. In: ClinicalTrialsgov [Internet] Bethesda (MD): National Library of Medicine (US) Available from: http://wwwclinicaltrialsgov/ ct2/show/NCT00990717?term=NCT00 990717&rank=1 NCT Identifier: NCT00990717. 2000-[cited 2011 Mar 16].